DBL Pharma with the slogan “Passion for Precision” aims to establish itself as a leading pharmaceutical company by focusing on research and development (R&D) with quality by design approach to produce high-quality medicines that meet international standards. DBL Pharmaceuticals has invested in advanced technologies and infrastructure to ensure the production of high-quality, safe, and effective pharmaceutical products. The company's facilities are designed to comply fully with the World Health Organization (WHO), United States Food and Drug Administration (US FDA) & European GMP regulations, ensuring the highest safety standards for patients.

DBL Pharmaceuticals offers a diverse range of pharmaceutical products, including antibiotics, analgesics, antihypertensives, antidiabetics, antihistamines, and vitamins and minerals. The company's product portfolio is designed to address a wide range of healthcare needs, from acute to chronic conditions, and cater to both local and international markets. DBL Pharmaceuticals' manufacturing facilities are equipped with state-of-the-art equipment, ensuring 21CFR Part 11 compliance of US FDA. fully digitalized quality management system (eQMS) with Master Control, and adhere to the highest quality standards. Also, DBL Pharma uses rigorous testing protocols and quality control measures throughout manufacturing to address potential impurity issues. Advanced analytical techniques are employed to ensure all products meet strict purity standards before reaching the market.

In addition, DBL Pharmaceuticals Inc., a concern of DBL Pharmaceuticals Ltd. is based in New York, USA. The company is currently holding ANDA of Methocarbamol and it was a surprise debut of DBL Pharmaceuticals Inc. as the third Bangladeshi initiative in the US Generic Medicine market even before launching DBL Pharma in local territory.